Medline (NASDAQ:MDLN) Stock Gets Price Target Boost from UBS Group

Medline (NASDAQ:MDLN) had its target price increased by analysts at UBS Group from $43.00 to $49.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group‘s price objective points to a potential upside of 23.61% from the company’s current price.

Other equities research analysts have also issued reports about the company. Citigroup increased their target price on Medline from $45.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday. Leerink Partners increased their price target on Medline from $43.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday. Zacks Research cut Medline from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 20th. Royal Bank Of Canada cut their price objective on Medline from $53.00 to $46.00 and set an “outperform” rating for the company in a report on Thursday, August 6th. Finally, Tigress Financial decreased their target price on Medline from $62.00 to $55.00 and set a “buy” rating for the company in a research note on Tuesday, August 11th. Twenty-three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Medline has an average rating of “Moderate Buy” and an average price target of $46.08.

Medline Stock Down 0.3%

Shares of MDLN traded down $0.12 during midday trading on Thursday, hitting $39.64. The company had a trading volume of 8,997,280 shares, compared to its average volume of 8,541,800. The company’s 50 day moving average price is $34.78 and its 200 day moving average price is $39.48. Medline has a 52 week low of $31.37 and a 52 week high of $50.88. The stock has a market cap of $52.12 billion and a price-to-earnings ratio of 90.09. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.12. The business had revenue of $7.86 billion for the quarter. On average, equities research analysts predict that Medline will post 1.49 EPS for the current year.

Insider Activity

In related news, major shareholder Private Ltd Gic sold 2,570,999 shares of Medline stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $35.35, for a total value of $90,884,814.65. Following the transaction, the insider directly owned 20,231,483 shares in the company, valued at $715,182,924.05. The trade was a 11.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders sold a total of 7,948,676 shares of company stock valued at $281,805,137 over the last quarter. 0.81% of the stock is currently owned by corporate insiders.

Institutional Trading of Medline

Large investors have recently added to or reduced their stakes in the company. Aberdeen Group plc purchased a new position in Medline in the third quarter valued at about $1,270,000. Russell Investments Group Ltd. increased its position in Medline by 4.1% during the third quarter. Russell Investments Group Ltd. now owns 310,908 shares of the company’s stock worth $10,789,000 after buying an additional 12,124 shares during the last quarter. Maryland State Retirement & Pension System raised its holdings in Medline by 17.4% during the third quarter. Maryland State Retirement & Pension System now owns 27,149 shares of the company’s stock valued at $942,000 after buying an additional 4,029 shares in the last quarter. Jefferies Financial Group Inc. raised its holdings in Medline by 330.3% during the third quarter. Jefferies Financial Group Inc. now owns 100,000 shares of the company’s stock valued at $3,470,000 after buying an additional 76,761 shares in the last quarter. Finally, MFF Capital Investments Ltd acquired a new stake in shares of Medline in the third quarter worth about $3,470,000.

Medline News Roundup

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Medline reported Q3 EPS of $0.44, beating the $0.32 consensus estimate, with revenue of $7.86 billion. Shares gapped higher following the earnings report. Medline shares gap up following strong earnings
• Positive Sentiment: Analyst target increases add to the bullish outlook: UBS raised its target to $49 and maintained a Buy rating; Citi raised its target to $47 and kept Buy; and Leerink Partners lifted its target to $46 with an Outperform rating. UBS ratings Citi ratings Leerink Partners ratings
• Positive Sentiment: BTIG reaffirmed its Buy rating with a $55 target, while Barclays also assigned a Buy rating, adding to the favorable analyst sentiment. BTIG ratings Barclays rating
• Positive Sentiment: Medline plans price increases in 2027 to offset inflation, which could help protect revenue and profitability if customers accept the higher prices. Pricing plans and Q3 results

Medline Company Profile

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations.

The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations.

Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.